Spots Global Cancer Trial Database for A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
Official Title: A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
Study ID: NCT05025085
Conditions
Study Description
Brief Summary: This study is a multicenter, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AGEN1777 as a single agent and when used in combination with a PD-1 inhibitor in participants with advanced, metastatic solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution - 165, Grand Rapids, Michigan, United States
START Midwest, Grand Rapids, Michigan, United States
Local Institution - 024, Southfield, Michigan, United States
Local Institution - 072, Cincinnati, Ohio, United States
University of Cincinnati Cancer Center, Cincinnati, Ohio, United States
Providence Cancer Institute, Portland, Oregon, United States
Lifespan Cancer Institute, Providence, Rhode Island, United States
Local Institution - 0001, Providence, Rhode Island, United States
Local Institution - 164, Dallas, Texas, United States
Mary Crowley Cancer Research, Dallas, Texas, United States
MD Anderson Cancer Center Thoracic-Head & Neck Med Onc, Houston, Texas, United States
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
